A number of other equities research analysts have also recently weighed in on MOR. Berenberg Bank set a €85.00 ($104.94) price target on MorphoSys and gave the company a buy rating in a research note on Tuesday. Royal Bank of Canada set a €57.00 ($70.37) price target on MorphoSys and gave the company a sell rating in a research note on Tuesday. JPMorgan Chase & Co. restated a buy rating and issued a price target on shares of MorphoSys in a research note on Tuesday. Commerzbank set a €98.00 ($120.99) price target on MorphoSys and gave the company a buy rating in a research note on Monday, March 12th. Finally, Deutsche Bank set a €94.00 ($116.05) price target on MorphoSys and gave the company a buy rating in a research note on Monday, March 12th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. The company currently has an average rating of Hold and a consensus target price of €84.02 ($103.73).
Shares of MorphoSys (ETR MOR) opened at €83.90 ($103.58) on Tuesday. MorphoSys has a 12 month low of €49.63 ($61.27) and a 12 month high of €88.10 ($108.77). The stock has a market capitalization of $2,490.00 and a P/E ratio of -34.81.
MorphoSys Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.